Navidea Biopharmaceuticals Inc : Navidea Biopharmaceuticals - On Feb 22, 2017, Co, CRG, and Cardinal Health 414 read into record a settlement in interpleader action pending in Ohio . Navidea Biopharmaceuticals Inc - Parties agreed that CRG will be paid $59 million - SEC filing . Navidea...
Reata announces initiation of phase 2/3 study of bardoxolone methyl in treatment of chronic kidney disease
Reata Pharmaceuticals Inc : Reata announces initiation of phase 2/3 study of bardoxolone methyl in the treatment of chronic kidney disease due to alport syndrome . Reata pharmaceuticals inc - expects data from phase 2 portion of trial to be available, and to decide on entering phase 3 portion, by...
Oncogenex Pharma believes cash, cash equivalents, short-term investments to be sufficient to fund currently planned operations for next 12 months
Oncogenex Pharmaceuticals Inc : Oncogenex pharma - believes cash, cash equivalents, short-term investments to be sufficient to fund currently planned operations for at least next 12 months . Oncogenex pharmaceuticals inc - revenue for q4 was zero .Oncogenex pharmaceuticals inc - net loss for q4 and...
No related earnings announcements are currently scheduled within the next 7 days.